[PDF][PDF] Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.
…, D Coyle, A Folkes, AA Joy, L Provencher, D Rayson… - 2011 - researchgate.net
… Joy, Louise Provencher, Daniel Rayson, Dorianne E. Rheaume, Geoffrey A. Porter,
Lawrence F. … Joy, Louise Provencher, Daniel Rayson, Dorianne E. Rheaume, Geoffrey A …
Lawrence F. … Joy, Louise Provencher, Daniel Rayson, Dorianne E. Rheaume, Geoffrey A …
Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis
…, S Dent, K Gelmon, A Paterson, D Rayson… - JAMA …, 2016 - jamanetwork.com
Importance The expense and lengthy follow-up periods for randomized clinical trials (RCTs)
of adjuvant systemic therapy in breast cancer make them impractical and even impossible to …
of adjuvant systemic therapy in breast cancer make them impractical and even impossible to …
Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy
…, BD Hayley, S Hopkins, AA Joy, D Rayson… - Canadian Journal of …, 2016 - Elsevier
Modern treatment strategies have led to improvements in cancer survival, however, these
gains might be offset by the potential negative effect of cancer therapy on cardiovascular health…
gains might be offset by the potential negative effect of cancer therapy on cardiovascular health…
Pegylated liposomal doxorubicin-associated hand–foot syndrome: recommendations of an international panel of experts
…, BJK Thuerlimann, M Aapro, D Rayson… - European journal of …, 2008 - Elsevier
BACKGROUND: Hand–foot syndrome (HFS) is dose-limiting and the most common
cumulative toxicity associated with pegylated liposomal doxorubicin (PLD). It can cause …
cumulative toxicity associated with pegylated liposomal doxorubicin (PLD). It can cause …
Molecular markers in male breast carcinoma
D Rayson, C Erlichman, VJ Suman… - … Journal of the …, 1998 - Wiley Online Library
BACKGROUND In contrast to female breast carcinoma, information regarding the prevalence
and prognostic information of new molecular markers is limited in male breast carcinoma. …
and prognostic information of new molecular markers is limited in male breast carcinoma. …
[HTML][HTML] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast …
…, J Beith, A Petzer, J Andrade, V Bernstein, D Rayson… - Annals of …, 2019 - Elsevier
Background Pertuzumab combined with trastuzumab and docetaxel is the standard first-line
therapy for HER2-positive metastatic breast cancer, based on results from the phase III …
therapy for HER2-positive metastatic breast cancer, based on results from the phase III …
Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus
…, J Rivera, R Wong, E Segelov, D Rayson - Cancer Treatment …, 2016 - Elsevier
The majority of neuroendocrine tumors originate in the digestive system and incidence is
increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis …
increasing within Canada and globally. Due to rapidly evolving evidence related to diagnosis …
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials
…, KA Gelmon, DM McLeod, SK Chia, D Rayson… - Cancer treatment …, 2012 - Elsevier
PURPOSE: Angiogenesis is critical for tumor growth and a promising therapeutic target. This
review will summarize and analyze data from clinical trials of anti-angiogenic agents in the …
review will summarize and analyze data from clinical trials of anti-angiogenic agents in the …
Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a Canadian National Expert Group
…, P Metrakos, T Mukhtar, J Pasieka, D Rayson… - Annals of surgical …, 2015 - Springer
Pancreatic neuroendocrine tumors (pNETs) are rare heterogeneous tumors that have been
steadily increasing in both incidence and prevalence during the past few decades. …
steadily increasing in both incidence and prevalence during the past few decades. …
Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial
M King, A Deveaux, H White, D Rayson - Supportive Care in Cancer, 2012 - Springer
Background Lymphedema as a result of curative surgery for breast cancer can lead to long-term
morbidity. Decongestive lymphatic therapy (DLT) is recognized as an optimal …
morbidity. Decongestive lymphatic therapy (DLT) is recognized as an optimal …